The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Petrikov A.S.

Altai State Medical University;
Diagnostic Center of Altai Territory

Dudin D.V.

Barnaul City Clinical Hospital No. 5

Dronov S.V.

Altai State University

Eyrikh V.R.

Barnaul City Clinical Hospital No. 4

Shoikhet Ya.N.

Altai State Medical University

Lower Extremity Deep Vein Recanalization Following Prolonged Antithrombotic Therapy and D-dimer, C-reactive Protein and Homocysteine Levels

Authors:

Petrikov A.S., Dudin D.V., Dronov S.V., Eyrikh V.R., Shoikhet Ya.N.

More about the authors

Journal: Journal of Venous Disorders. 2020;14(3): 196‑204

Read: 3096 times


To cite this article:

Petrikov AS, Dudin DV, Dronov SV, Eyrikh VR, Shoikhet YaN. Lower Extremity Deep Vein Recanalization Following Prolonged Antithrombotic Therapy and D-dimer, C-reactive Protein and Homocysteine Levels. Journal of Venous Disorders. 2020;14(3):196‑204. (In Russ.)
https://doi.org/10.17116/flebo202014031196

Recommended articles:
Fibrin mono­mer in diagnosis of cardiovascular diseases. Russian Cardiology Bulletin. 2024;(4-2):113-120
The level of hypo­xia-induced factor-1a and asso­ciated mole­cules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10
Signs of high embo­lic risk in iliocaval floating thro­mbi. Piro­gov Russian Journal of Surgery. 2025;(3):56-62
Evaluation of prognostic factors of preterm birth. Russian Journal of Human Reproduction. 2025;(2):37-43
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Modern approach to the treatment of acute iliofemoral thro­mbosis. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):293-299

References:

  1. Bokeria LA, Zatevakhin II, Kirienko AI, Andriyashkin AV, Andriyashkin VV, Arutyunov GP, Barinov VE, Bitsadze VO, Bodykhov MK, Britov AN, Butenko AV, Vavilova TV, Vorobyeva NA, Voskanyan YuE, Gavrilenko AV, Galstyan GM, Gelfand BR, Gilyarov MYu, Golubev GSh, Zamyatin MN. Russian Clinical Guidelines for the Diagnostics, Treatment and Prevention VTE. Flebologiya. 2015;4(2):10-17. (In Russ.)
  2. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease. CHEST journal. Official publication of the American college of chest physician. 2016; 149(2):315-352.  https://doi.org/10.1016/j.chest.2015.11.026
  3. Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, McLeod A, Strulovitch C, Blostein M, Faucher JP, Gamble G, Gordon W, Kagoma PK, Miron MJ, Laverdière D, Game M, Mills A. Management and adherence to VTE treatment guidelinesin a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thrombosis and Haemostasis. 2012;108(3):493-498.  https://doi.org/10.1160/TH12-03-0169
  4. Goldhaber S, Visani L, Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386-1389. https://doi.org/10.1016/S0140-6736(98)07534-5
  5. Denny N, Musale S, Edlin H, Serracino-Inglott F, Thachil J. Iliofemoral deep vein thrombosis and the problem of post-thrombotic syndrome. Acute Medicine. 2018;17(2):99-103. 
  6. Petrikov AS, Dudin DV, Shoykhet YaN, Belykh VI, Prostov II. Recanalization of deep vein proximal thrombosis against a background of prolonged antiplatelet therapy. Russkij meditsinskij zhurnal. 2019;27(2):25-30. (In Russ.)
  7. Shevchenko YuL, Stoyko YuM. Osnovy klinicheskoj flebologii. M.: Shiko; 2013. (In Russ.)
  8. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309-1312.
  9. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, Poli D, Lim W. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149:481-490, W94.  https://doi.org/10.7326/0003-4819-149-7-200810070-00008
  10. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooler analysis. RE — COVER II Trail Investigation. Circulation. 2014; 129(7):764-772.  https://doi.org/10.1161/CIRCULATIONAHA.113.004450
  11. Petrikov AS, Dudin DV, Valova OV, Eyrikh VR, Zaytsev SV, Shoykhet YaN. Possibilities of long-lasting anti-thrombotic therapy in patients with proximal thrombosis of lower limbs deep veins. Vestnik SurGU. Meditsina. 2018;36(2): 37-44. (In Russ.)
  12. Petrikov AS, Belykh VI, Shoihet YaN. Features of tower extremities deep veins recanalization in patients with thrombosis by using of Sulodexide. Khirurgiya. Zhurnal im. N.I. Pirogova. 2015;6:58-64. (In Russ.) https://doi.org/10.17116/hirurgia2015658-64
  13. Elmi G, Pizzini AM, Silingardi M. The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy. Vascular. 2018;26(6):670-682.  https://doi.org/10.1177/1708538118776896
  14. Kazakov AS, Astakhova AV, Lepakhin VK. Rivaroxaban: the risk of development of undesirable reactions of interaction. Rossijskij meditsinskij zhurnal. 2014;20(2):31-36. (In Russ.)
  15. Borawski J, Dubowski M, Rydzewska-Rosolowska A, Mysliwiec M. Intravenous and oral sulodexide versus coagulation activation markers in humans. Clinical and Applied Thrombosis/Hemostasis. 2009;15(5):596-598.  https://doi.org/10.1177/1076029609333674
  16. Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, Pawlaczyk-Gabriel K, Džupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visonà A. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015;132(20): 1891-1897. https://doi.org/10.1161/CIRCULATIONAHA.115.016930
  17. Kunutsor SK, Seidu S, Blom AW, Khunti K. Laukkanen JA. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. European Journal of Epidemiology. 2017;32(8):657-667.  https://doi.org/10.1007/s10654-017-0277-4
  18. Grimnes G, Isaksen T, Tichelaar YIGV, Brox J, Brækkan SK, Hansen JB. C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study. Haematologica. 2018;103(7): 1245-1250. https://doi.org/10.3324/haematol.2017.186957
  19. Komarów W, Hawro P, Lekston A, Urbanek T, Zagrodzki P. Endothelial dysfunction in patients with chronic venous disease: an evaluation based on the flow-mediated dilatation test. International Angiology: a journal of the International Union of Angiology. 2015;34(1):36-42. 
  20. Tanaka M, Taniguchi T, Saito N, Kimura T. Inferior vena cava thrombus due to hyperhomocysteinemia. Journal of Cardiology Cases. 2018;18(5):168-170.  https://doi.org/10.1016/j.jccase.2018.07.003
  21. Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, Folsom AR, Zakai NA. Inflammation markers and incident venous thromboembolism: the reasons for geographic and racial differences in stroke (REGARDS) cohort. Thrombosis and Haemostasis. 2014;12(12):1993-2001. https://doi.org/10.1111/jth.12742
  22. Petrikov AS, Dudin DV, Popkova LN, Volodin IV, Shoikhet YaN. Clinical course of deep venous thrombosis of lower limbs in acute period with underlying anticoagulant therapy depending on concentration of D-dimers and C-reactive protein. Nauka molodykh (Eruditio Juvenium). 2018;6(2):233-241. (In Russ.) https://doi.org/10.23888/HMJ201862233-241
  23. Churikov DA, Kirienko AI. Ultrazvukovaya diagnostika boleznej ven. M.: Litterra; 2016. (In Russ.)
  24. Dronov SV. Metody i zadachi mnogomernoj statistiki. Barnaul: Publishing house of AltSU; 2015 (In Russ.)
  25. Jezovnik MK, Poredos P. Factors influencing the recanalisation rate of deep venous thrombosis. Int Angiol. 2012;31(2):169-175. 
  26. Zhang C, Fu Q, Zhao Y, Mu S, Liu L. Short-Term Anticoagulant Therapy and Thrombus Location Are Independent Risk Factors for Delayed Recanalization of Deep Vein Thrombosis. Med Sci Monit. 2016;22:219-225.  https://doi.org/10.12659/msm.895228
  27. Liu D, Peterson E, Dooner J, Baerlocher M, Zypchen L, Gagnon J, Delorme M, Sing CK, Wong J, Guzman R, Greenfield G, Moodley O, Yenson P; Interdisciplinary Expert Panel on Iliofemoral Deep Vein Thrombosis (InterEPID). Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline. CMAJ. 2015;187(17):1288-1296. https://doi.org/10.1503/cmaj.141614
  28. Rich K. Iliofemoral deep vein thrombosis: Percutaneous endovascular treatment options. J Vasc Nurs. 2015;33(2):47-53. 
  29. Jeraj L, Jezovnik MK, Poredos P. Insufficient Recanalization of Thrombotic Venous Occlusion-Risk for Postthrombotic Syndrome. J Vasc Interv Radiol. 2017;28(7):941-944.  https://doi.org/10.1016/j.jvir.2017.03.031
  30. Piati PK, Peres AK, de Andrade DO, Jorge MA, Toregeani JF. Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs rivaroxaban. J Vasc Bras. 2019;18:e20180111. https://doi.org/10.1590/1677-5449.180111
  31. Vorobyeva NM, Panchenko EP. Antikoagulyantnaya terapiya venoznykh tromboembolicheskikh oslozhnenij: problemy i perspektivy. Rossijskij kardiologicheskij zhurnal. 2015;3(119):7-17. (In Russ.)
  32. Poredoš P, Spirkoska A, Ježovnik MK. In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate. Arch Med Sci. 2019;15(2):393-401.  https://doi.org/10.5114/aoms.2019.83292
  33. Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11): 1478-1493. https://doi.org/10.2174/138161212799504731
  34. Collen D, Hoylaerts MF. Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma. J Am Coll Cardiol. 2005;45:1472-1473.
  35. Müller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003;17: 476-478.  https://doi.org/10.1096/fj.02-0574fje
  36. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1: 1343-1348.
  37. Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. Front Pediatr. 2018;6:142.  https://doi.org/10.3389/fped.2018.00142
  38. Kaczyńska A, Kostrubiec M, Pacho R, Kunikowska J, Pruszczyk P. Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism. Thromb Res. 2008;122(1):21-25.  https://doi.org/10.1016/j.thromres.2007.08.020

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.